Table 1.

Baseline patient characteristics according to the expression of PGC-1α in blood samples

	All patients (n=35)	Patients with peripheral PGC-1α expression >2 -fold (n=11)	Patients with peripheral PGC-1α expression <2 -fold (n=24)	P
Age, years	69.8±11.9	63.3±15.7	72.6±8.8	0.10
Male, n (%)	19 (54)	7 (64)	12 (50)	0.22
Cardiovascular risk factors, n (%)
Hypertension	29 (83)	9 (82)	20 (83)	0.91
Diabetes	9 (26)	1 (9)	8 (33)	0.13
Dyslipidemia	22 (63)	6 (55)	16 (67)	0.50
Smoking history	18 (51)	7 (64)	11 (46)	0.34
Medication, n (%)
ACEI or ARB	23 (66)	7 (64)	16 (67)	0.52
Diuretics	24 (69)	6 (55)	18 (75)	0.24
Beta-blockers	14 (40)	7 (64)	7 (29)	0.07
Estatins	20 (57)	6 (55)	14 (58)	0.84
Metformin	6 (17)	1 (9)	5 (21)	0.14
ODM	3 (9)	1 (9)	2 (9)	0.92
Insulin	4 (12)	0 (0)	4 (18)	0.14
Laboratory
Hemoglobin, g/dL	13.1±1.1	13.4±1.2	12.9±1.1	0.15
Creatinine, mg/dL	0.8±0.2	0.9±0.2	0.8±0.3	0.62
Hb1Ac (%)	6.2±0.6	6.0±0.9	6.6±0.5	0.36
Echocardiography
LVEF (%)	60.4±10.3	59.4±14.2	60.9±8.2	0.72
LVEDD, mm	48.8±9.4	51.6±10.9	47.5±8.5	0.20
LVESD, mm	30.7±9.0	33.9±10.5	29.1±8.0	0.23
TAPSE, mm	22.7±6.0	24.0±4.7	22.1±6.6	0.40
sPAP, mm Hg	39.1±9.9	35.5±8.2	40.8±10.3	0.11
Coronarography
CAD, n (%)	8 (23)	5 (45)	3 (13)	0.03
VSS	0.2±0.6	0.4±0.9	0.2±0.5	0.41
History of heart failure
NYHA functional class	2.7±0.5	2.6±0.5	2.7±0.5	0.87

ACEI - angiotensin-converting enzyme inhibitor; ARB - angiotensin II receptor blocker; CAD - coronary artery disease; LVEF - left ventricular ejection fraction; LVEDD - left ventricular end-diastolic diameter; LVESD - left ventricular end-diastolic end-systolic diameter; ODM - other oral an diabetic medication; sPAP - systolic pulmonary artery pressure; TAPSE - tricuspid annular plane systolic excursion; VSS - No of vessels with significant stenosis. Comparisons between both groups were made by chi-square and unpaired Student’s t-tests. Quantitative data expressed as mean±standard deviation. Significant if p<0.05